Phaseline

Targets › CHRM3

CHRM3 (Muscarinic acetylcholine receptor M3): drug programs, companies and trials

32 programs from 28 companies in 144 trials: 51 Phase 3, 38 Phase 4, 33 Phase 2, 22 Phase 1; Respiratory, Other, Ophthalmology; next expected readout Nov 2026.

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P20309)

Open in Phaseline: the race on CHRM3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbTrospium Chloride
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania …Nov 2026
Bristol-Myers SquibbTrospium Chloride (BMS-986510)
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; SchizophreniaNov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of Tennessee Graduate School of MedicineRevefenacin
Muscarinic acetylcholine receptor M3 antagonist
CHRM3Phase 4COPD (Chronic Obstructive Pulmonary Disease)Dec 2026
Mackay Memorial HospitalSolifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Effect of Drug; Urinary Bladder, OveractiveDec 2026
Dr. J. Alberto NederIpratropium
Muscarinic acetylcholine receptor M3 antagonist
CHRM3Phase 4COPDJan 2027
GSKUmeclidinium
Muscarinic acetylcholine receptor M3 antagonist
CHRM3Phase 4Asthma; COPD (Chronic Obstructive Pulmonary Disease); Chronic Obstructive Pulmonary Disease (COPD)Jun 2027
Mansoura UniversitySolifenacin succinate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Overactive Bladder (OAB); Nocturnal Enuresis in ChildrenJun 2027
University of AarhusSolifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Urinary Incontinence in ChildrenOct 2027
AstraZenecaBreztri Aerosphere
Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis
ADRB2, CHRM3Phase 4Moderate to Severe COPDDec 2027
Sairam ParthasarathyAtomoxetine-oxybutynin
Norepinephrine reuptake inhibitor combined with muscarinic-3 receptor antagonist to increa
SLC6A2, CHRM3Phase 4Obstructive Sleep Apnea (OSA)Mar 2030
Southern College of OptometryPilocarpine
Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM3, CHRM1Phase 4Presbyopia–
University of California, DavisOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Overactive Bladder SyndromeDec 2026
Bir HospitalSolifenacin Succinate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Ureteral Stent-Related SymptomDec 2026
GSKFF/UMEC/VI
Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination
CHRM3, ADRB2Phase 3AsthmaJan 2027
AstraZenecaBGF MDI 320/14.4/9.6 μg
Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g
ADRB2, CHRM3Phase 3COPD (Chronic Obstructive Pulmonary Disease)Dec 2027
Ocus Innovation IrelandAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3MyopiaDec 2027
Oslo University HospitalBuscopan 20 MG/ML Injectable Solution
Anticholinergic agent that reduces smooth muscle spasms
CHRM1, CHRM3Phase 3Labor ComplicationDec 2027
Central Hospital, Nancy, FranceOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Spina BifidaJan 2028
Montefiore Medical CenterPilocarpine
Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM3, CHRM1Phase 3GlaucomaJun 2028
Chiesi FarmaceuticiCHF 5993 100/6/12.5 μg pMDI HFA-152a
Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting
ADRB2, CHRM3Phase 3AsthmaOct 2028
Sherief Abd-Elsalamorphenadrine
Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain
CHRM1, CHRM2, CHRM3Phase 3Liver CirrhosisDec 2028
Reinier de Graaf GroepOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 3Breast CancerJan 2029
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3Myopia; Achalasia; Progressive Myopia; Focus on Axial Length …–
Belfast Health and Social Care TrustAtropine Sulfate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 2MyopiaFeb 2027
NovartisGlycopyrronium bromide
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist
CHRM3, CHRM1Phase 2Asthma; Post-Dural Puncture HeadacheJul 2027
Oliver BlanchardDarifenacin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Amyotrophic Lateral SclerosisOct 2027
University of VirginiaAnoro Ellipta
Long-acting muscarinic antagonist (umeclidinium) + long-acting beta-2 agonist (vilanterol)
CHRM3, ADRB2Phase 2Chronic Obstructive Pulmonary DiseaseJan 2028
University Hospital, BordeauxOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Male Urogenital DiseasesFeb 2028
AstraZenecaGlycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
University of ArizonaOxybutynin
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 2Obstructive Sleep Apnea–
University Hospital, LilleTRIXEO AEROSPHERE (BGF 160)
Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic
ADRB2, CHRM3, NR3C1Phase 1Copd–

Conditions

Myopia (17) Asthma (7) Schizophrenia (6) Alzheimer Disease (4) Healthy Volunteers (4) Alzheimer's Disease (3) Psychosis Associated With Alzheimer's Disease (3) COPD (Chronic Obstructive Pulmonary Disease) (3) Nicotine Dependence (3) Progressive Myopia (2) Myopia, Progressive (2) Urinary Incontinence in Children (2)

Modalities

small molecule (30), protein or peptide (1)

Companies

AstraZeneca (3) Bristol-Myers Squibb (2) GSK (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) University of Arizona (1) Bir Hospital (1) University of Aarhus (1) University of Virginia (1) Reinier de Graaf Groep (1) Montefiore Medical Center (1) Ocus Innovation Ireland (1) University Hospital, Bordeaux (1) University of California, San Francisco (1) Belfast Health and Social Care Trust (1) Oslo University Hospital (1) Mackay Memorial Hospital (1) Chiesi Farmaceutici (1) Dr. J. Alberto Neder (1) Sairam Parthasarathy (1) Central Hospital, Nancy, France (1)

Related targets

CHRM2 (18) CHRM1 (9) ADRB2 (7) NR3C1 (2) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.